North China Pharmaceutical Company.Ltd (SHA:600812)
China flag China · Delayed Price · Currency is CNY
5.18
+0.38 (7.92%)
Sep 10, 2026, 2:35 PM CST

SHA:600812 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
8,1099,1389,79810,07010,44910,304
Other Revenue
76.96103.9971.7650.3251.1980.2
8,1869,2429,87010,12010,50010,385
Revenue Growth
-17.42%-6.36%-2.48%-3.62%1.11%-9.64%
Cost of Revenue
5,7316,3636,7326,9077,0636,691
Gross Profit
2,4562,8783,1383,2133,4373,694
Selling, General & Admin
1,4931,7802,0102,2682,4242,796
Research & Development
351.48339.77336.15294.2215.17151.93
Other Operating Expenses
80.2687.4190.82104.23117.57123.33
Operating Expenses
1,9392,2512,4792,6772,8023,094
Operating Income
516.51627.16658.87536.44634.8600.11
Interest Expense
-322.42-361.55-458.7-501.9-599.39-642.69
Interest & Investment Income
88.7886.4471.4274.5284.17126.62
Currency Exchange Gain (Loss)
-28.09-4.9617.5711.4923.31-8.32
Other Non Operating Income (Expenses)
-8.08-5.298.92-11.35-748.96-13.91
EBT Excluding Unusual Items
246.7341.81298.08109.2-606.0761.82
Impairment of Goodwill
---3.34---
Gain (Loss) on Sale of Assets
1.050.830.440.760.213.4
Asset Writedown
-0.76-0.76-1.4-0.05--
Legal Settlements
-1.93-1.72-0.5-0.49-0.78-1.14
Other Unusual Items
22.2317.2516.5549.1241.5670.84
Pretax Income
267.3357.41309.83158.54-565.07134.91
Income Tax Expense
81.2699.9694.87109.15113.7199.52
Earnings From Continuing Operations
186.04257.45214.9749.39-678.7835.38
Minority Interest in Earnings
-62.63-74.4-87.97-44.5-10.45-16.65
Net Income
123.4183.06126.994.89-689.2318.73
Net Income to Common
123.4183.06126.994.89-689.2318.73
Net Income Growth
-30.87%44.15%2496.79%---80.76%
Shares Outstanding (Basic)
1,7161,7111,7161,6301,7151,702
Shares Outstanding (Diluted)
1,7161,7111,7161,6301,7151,702
Shares Change
-0.05%-0.31%5.27%-4.92%0.70%4.96%
EPS (Basic)
0.070.110.070.00-0.400.01
EPS (Diluted)
0.070.110.070.00-0.400.01
EPS Growth
-30.84%44.59%2366.67%---81.67%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
673.2634.53445.35401.23454.81502.75
Free Cash Flow Per Share
0.390.370.260.250.270.29
Dividend Per Share
0.0350.0350.0300.010-0.060
Dividend Growth
16.67%16.67%200.00%--100.00%
Gross Margin
30.00%31.15%31.79%31.75%32.73%35.57%
Operating Margin
6.31%6.79%6.68%5.30%6.05%5.78%
Profit Margin
1.51%1.98%1.29%0.05%-6.56%0.18%
Free Cash Flow Margin
8.22%6.87%4.51%3.96%4.33%4.84%
EBITDA
1,4471,5171,4521,2751,3471,224
EBITDA Margin
17.68%16.41%14.71%12.60%12.83%11.79%
D&A For EBITDA
930.75889.37792.99739.01712624
EBIT
516.51627.16658.87536.44634.8600.11
EBIT Margin
6.31%6.79%6.68%5.30%6.05%5.78%
Effective Tax Rate
30.40%27.97%30.62%68.85%-73.77%
Revenue as Reported
8,1869,2429,87010,12010,50010,385
Advertising Expenses
-109.62119.86133.01127.89185.19